Table 1Pairwise comparisons of interventions with number of studies and patients

Intervention + MTXaControl + MTXaNumber of studiesNumber of patientsb
AbataceptPlacebo62679
AdalimumabPlacebo61508
AnakinraPlacebo21653
Certolizumab pegolPlacebo41286
EtanerceptPlacebo2548
EtanerceptcSulfasalazinec171
(MTX intolerance)
EtanerceptcMTXc141
(patients with severe active and progressive RA)
GolimumabPlacebo2401
 (no previous treatment with TNF-α inhibitors)
Placebo1205
 (previous treatment with TNF-α inhibitors)
InfliximabPlacebo1174
RituximabPlacebo1520
 (no previous treatment with rituximab)
Placebo1475
 (after a lack of response to a cycle of rituximab)
TocilizumabPlacebo52836
 (largely no previous treatment with TNF-α inhibitors)
Placebo1335
 (previous treatment with TNF-α inhibitors)
Direct comparison:
TocilizumabcAdalimumabc1326
(Patients who were not suitable for further treatment with MTX)
Sum:3513,058
a

If not otherwise stated.

b

Relevant populations for the present assessment.

c

Monotherapy.

MTX: methotrexate, RA: rheumatoid arthritis, TNF: tumour necrosis factor

If not otherwise stated.

Relevant populations for the present assessment.

Monotherapy.

© IQWiG (Institute for Quality and Efficiency in Health Care)

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.